Vincerx Pharma, Inc. (VINC)

USD 0.22

(12.97%)

Market Cap (In USD)

7.29 Million

Revenue (In USD)

-

Net Income (In USD)

-40.15 Million

Avg. Volume

189.57 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.183-9.372
PE
-
EPS
-
Beta Value
1.267
ISIN
US92731L1061
CUSIP
92731L106
CIK
1796129
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ahmed M. Hamdy M.D.
Employee Count
-
Website
https://vincerx.com
Ipo Date
2020-05-27
Details
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.